Oncology Drugs to Watch 2021
16 July 2021 | Friday | Analysis
Key therapeutic candidates and forces shaping the oncology marketplace
Image Source : Public Domain
In this oncology edition of our Drugs to WatchTM series, Clarivate experts explore treatment breakthroughs highlighted at the ASCO Annual Meeting 2021, the biggest oncology event of the year, and provide analysis on how these will reshape the oncology landscape.
Key highlights from the report:
- Early-stage focus of most prominent treatments
- Gastroesophageal cancers as an emerging area of focus for biopharma
- Clash of the PD-1/PD-L1 titans
- Mainland China as an oncology powerhouse
Click here to Download an exclusive report
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
